Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.
Garakani A, Alexander JL, Sumner CR, Pine JH, Gross LS, Raison CL, Aaronson ST, Baron DA. Garakani A, et al. Among authors: aaronson st. J Psychiatr Pract. 2023 Sep 1;29(5):345-353. doi: 10.1097/PRA.0000000000000729. J Psychiatr Pract. 2023. PMID: 37678363 Review.
Assessing potential of psilocybin for depressive disorders.
Kozak Z, Johnson MW, Aaronson ST. Kozak Z, et al. Among authors: aaronson st. Expert Opin Investig Drugs. 2023 Jul-Dec;32(10):887-900. doi: 10.1080/13543784.2023.2273493. Epub 2023 Nov 6. Expert Opin Investig Drugs. 2023. PMID: 37869790 Review.
Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report.
Conway CR, Aaronson ST, Sackeim HA, Duffy W, Stedman M, Quevedo J, Allen RM, Riva-Posse P, Berger MA, Alva G, Malik MA, Dunner DL, Cichowicz I, Luing H, Zajecka J, Nahas Z, Mickey BJ, Kablinger AS, Kriedt CL, Bunker MT, Lee YL, Shy O, Majewski S, Olin B, Tran Q, Rush AJ. Conway CR, et al. Among authors: aaronson st. Brain Stimul. 2024 Mar-Apr;17(2):448-459. doi: 10.1016/j.brs.2024.03.016. Epub 2024 Apr 2. Brain Stimul. 2024. PMID: 38574853 Free article. Clinical Trial.
Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study.
Cutler AJ, Mattingly GW, Kornstein SG, Aaronson ST, Lasser R, Zhang H, Rana N, Brown C, Levin S, Miller C, Kotecha M, Forrestal F, Doherty J. Cutler AJ, et al. Among authors: aaronson st. J Clin Psychiatry. 2023 Dec 27;85(1):23m14845. doi: 10.4088/JCP.23m14845. J Clin Psychiatry. 2023. PMID: 38153320 Free article. Clinical Trial.
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Parikh SV, Aaronson ST, Mathew SJ, Alva G, DeBattista C, Kanes S, Lasser R, Bullock A, Kotecha M, Jung J, Forrestal F, Jonas J, Vera T, Leclair B, Doherty J. Parikh SV, et al. Among authors: aaronson st. Neuropsychopharmacology. 2024 Jan;49(2):467-475. doi: 10.1038/s41386-023-01751-9. Epub 2023 Oct 24. Neuropsychopharmacology. 2024. PMID: 37875578 Free PMC article. Clinical Trial.
56 results